Sign in to view content

Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies

David M. Brown, MD

Video
Published 2021

Related

Reduction in the Frequency of Diabetic Macular Edema (DME) Therapies Post-0.2 ug/Day Fluocinolone Acetonide (FAc) Implant Treatment Results
Sam E. Mansour, MD, MSc,FACS, FRCS(C)
Annual Meeting Talks
2018
Characteristics and the Need for Supplementation Following 0.19mg Fluocinolone Acetonide (FAc) in Diabetic Macular Edema (DME) Patients
Victor Hugo Gonzalez, MD
Annual Meeting Talks
2021
Elevatum Study Design and Rationale: A Phase 4 Trial of Faricimab (VABYSMO) in Underrepresented Patients With Diabetic Macular Edema
Joseph M. Coney, MD, FASRS
Annual Meeting Talks
2023

Category: Pharmacology

See more